专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5401778A Biodegradable plastic composition and biodegradable plastic shaped body 失效
标题翻译：生物降解塑料成分和生物降解塑料成型体
公开(公告)号：US5401778A
公开(公告)日：1995-03-28
申请号：US44386
申请日：1993-04-07
申请人： Yutaka Tokiwa , Akira Iwamoto , Masahiro Harada , Shigeki Imagawa , Teizi Urakami
发明人： Yutaka Tokiwa , Akira Iwamoto , Masahiro Harada , Shigeki Imagawa , Teizi Urakami
IPC分类号： C08L67/04 , C08G63/06 , C08G63/08
CPC分类号： C08L67/04
摘要： A biodegradable plastic composition for forming biodegradable shaped bodies which includes a poly-.beta.-hydroxybutyrate having a viscosity of n.sub.A at 185.degree. C. and a polycaprolactone having a viscosity of n.sub.B at 185.degree. C., wherein the poly-.beta.-hydroxybutyrate is present in an amount C.sub.A of 10-45 or 55-85% by weight based on the total weight of the poly-.beta.-hydroxybutyrate and the polycaprolactone, and wherein n.sub.A, n.sub.B and C.sub.A satisfy the following condition:4.times.10.sup.-3 .times.C.sub.A -1.7.ltoreq.log (n.sub.A /n.sub.B).ltoreq.4.times.10.sup.-3 .times.C.sub.A -1.3.
摘要翻译：一种用于形成可生物降解的成形体的可生物降解的塑料组合物，其包括在185℃下具有nA粘度的聚-β-羟基丁酸酯和在185℃下具有nB粘度的聚己内酯，其中存在聚-β-羟基丁酸酯基于聚-β-羟基丁酸酯和聚己内酯的总重量，其重量为10-45或55-85重量％，其中nA，nB和CA满足以下条件：4×10-3×CA-1.7 < = log（nA / nB）

2. 发明授权

US5200332A Process for preparation of copolymer 失效
标题翻译：制备共聚物的方法
公开(公告)号：US5200332A
公开(公告)日：1993-04-06
申请号：US759919
申请日：1991-09-13
申请人： Tsuneo Yamane , Shunsaku Ueda , Shigeki Imagawa , Torakazu Tahara , Yoshiharu Tokunaga , Hiroyuki Iesaka , Teizi Urakami
发明人： Tsuneo Yamane , Shunsaku Ueda , Shigeki Imagawa , Torakazu Tahara , Yoshiharu Tokunaga , Hiroyuki Iesaka , Teizi Urakami
IPC分类号： C08G63/06 , C12P7/62
CPC分类号： C08G63/06 , C12P7/625 , Y10S435/822 , Y10S435/829 , Y10S435/831
摘要： Disclosed is a process for the preparation of a copolymer, which comprises propagating cells of a bacterium having a capacity of producing poly-3-hydroxybutyrate mainly at a former stage, synthesizing and accumulating in the cells a copolymer comprising D-3-hydroxybutyrate and D-3-hydroxyvalerate by contacting the bacterium with a mixture of a carbon source utilizable by the bacterium and a primary alcohol having 3 to 7 carbon atoms, or with a primary alcohol having 3 to 7 carbon atoms, at a latter stage, and recovering the copolymer from the cells. According to this process, a copolymer comprising D-3-hydroxybutyrate and D-3-hydroxyvalerate can be manufactured in a large quantity at a low cost.

3. 发明授权

US5429940A Process for producing oxazopyrroloquinolines, novel oxazopyrroloquinolines, and use of oxazopyrroloquinolines 失效
标题翻译：制备恶唑并吡咯并喹啉的方法，新型恶唑并吡咯啉喹啉和恶唑并吡咯啉喹啉的使用
公开(公告)号：US5429940A
公开(公告)日：1995-07-04
申请号：US060240
申请日：1993-07-12
申请人： Teizi Urakami , Mitsunori Oda , Chieko Itoh , Hisao Kobayashi , Toshio Nagai , Kazuhiro Sugamura
发明人： Teizi Urakami , Mitsunori Oda , Chieko Itoh , Hisao Kobayashi , Toshio Nagai , Kazuhiro Sugamura
IPC分类号： C07D498/14 , C12P17/18 , A61K31/435 , C12P17/16
CPC分类号： C07D498/14 , C12P17/188 , Y10S435/822 , Y10S435/863
摘要： The present invention provides a process for producing oxazopyrroloquinolines which comprises culturing microorganisms to produce pyrroloquinolinequinone and adding .alpha.-amino acids or monomethylamine to the resulting culture broth which contains the pyrroloquinolinequinone and from which cells of microorganisms are not separated, thereby to convert the pyrroloquinolinequinone to the corresponding oxazopyrroloquinolines. The thus obtained oxazopyrroloquinolines include novel compounds. The present invention further provides aldose reductase inhibitors, diabetic combined disease curing agents, immunopotentiating agents and liver disease inhibiting agents which contain as active ingredient these oxazopyrroloquinolines having excellent physiological activity.
摘要翻译：本发明提供一种生产恶唑并吡咯并喹啉的方法，其包括培养微生物以产生吡咯并喹啉醌，并向所得的含有吡咯并喹啉醌的培养液中加入α-氨基酸或一甲基胺，并且微生物细胞未分离，从而将吡咯并喹啉醌转化为对应的恶唑并吡咯啉喹啉。由此获得的恶唑并吡咯啉喹啉包括新化合物。本发明还提供了具有优异生理活性的醛糖还原酶抑制剂，糖尿病合并疾病固化剂，免疫增强剂和肝病抑制剂，其含有作为活性成分的恶唑吡咯并喹啉。

4. 发明授权

US4229543A Process for culturing methanol-utilizing yeasts 失效
标题翻译：培养甲醇利用酵母的方法
公开(公告)号：US4229543A
公开(公告)日：1980-10-21
申请号：US941641
申请日：1978-09-12
申请人： Kenzo Tonomura , Teizi Urakami
发明人： Kenzo Tonomura , Teizi Urakami
IPC分类号： C12N1/32 , C12N1/36 , C12N1/16
CPC分类号： C12N1/32
摘要： A process for culturing methanol-utilizing yeasts, wherein a methanol-utilizing yeast is cultured in a medium containing methanol as a main carbon source, using as seeds yeast cells obtained by culturing the yeast in a culture liquor containing methanol at a concentration higher than 0.1 wt. % and not more than 6 wt. %.
摘要翻译：培养使用甲醇的酵母的方法，其中使用甲醇的酵母在含有甲醇作为主要碳源的培养基中培养，使用通过在含有浓度高于0.1的甲醇的培养液中培养酵母而获得的酵母细胞重量％且不超过6重量％％。

5. 发明授权

US5846977A Nerve growth factor production accelerators and compositions for preventing or treating neuronal degeneration 失效
标题翻译：神经生长因子生产促进剂和预防或治疗神经元变性的组合物
公开(公告)号：US5846977A
公开(公告)日：1998-12-08
申请号：US675385
申请日：1996-07-02
申请人： Tomoko Tsuji , Kohji Yamaguchi , Kiyosi Kondo , Teizi Urakami
发明人： Tomoko Tsuji , Kohji Yamaguchi , Kiyosi Kondo , Teizi Urakami
IPC分类号： A61K31/47 , A61K31/4745 , A61K31/44
CPC分类号： A61K31/4745 , A61K31/47
摘要： Nerve growth factor production accelerating agents containing oxazopyrroloquinolines, pyrroquinolinequinones and/or their esters as active ingredient are provided. As the oxazopyrroloquinolines and their esters exhibit such production accelerating activity, they are suitably utilized for preventing and treating functional disorders of central nervous system, particularly, Alzheimer's dementia, cerebral ischemia and spinal trauma, as well as for functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma and diabetic neurosis. As the pyrroquinolinequinones and their esters exhibit strong nerve growth factor production accelerating activity, they are suitably utilized for preventing and treating functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma, diabetic neurosis, etc.
摘要翻译：提供含有恶唑吡咯并喹啉，吡咯醌啉醌和/或其酯作为活性成分的神经生长因子生产促进剂。由于恶唑吡咯并喹啉及其酯类具有这种生产促进活性，因此适用于预防和治疗中枢神经系统功能紊乱，特别是阿尔茨海默氏痴呆，脑缺血和脊髓损伤，以及周围神经系统的功能障碍，外周神经系统创伤和糖尿病性神经症。由于吡咯醌及其酯显示强烈的神经生长因子生产促进活性，因此适用于预防和治疗周围神经系统功能紊乱，特别是周围神经系统创伤，糖尿病性神经症等。

6. 发明授权

US5589481A Nerve growth factor production accelerators and compositions for preventing or treating neuronal degeneration 失效
标题翻译：神经生长因子生产促进剂和预防或治疗神经元变性的组合物
公开(公告)号：US5589481A
公开(公告)日：1996-12-31
申请号：US200912
申请日：1994-02-22
申请人： Tomoko Tsuji , Kohji Yamaguchi , Kiyosi Kondo , Teizi Urakami
发明人： Tomoko Tsuji , Kohji Yamaguchi , Kiyosi Kondo , Teizi Urakami
IPC分类号： A61K31/47 , A61K31/4745 , A61K31/44
CPC分类号： A61K31/4745 , A61K31/47
摘要： Nerve growth factor production accelerating agents containing oxazopyrroloquinolines, pyrroquinolinequinones and/or their esters as active ingredient are provided. As the oxazopyrroloquinolines and their esters exhibit such production accelerating activity, they are suitably utilized for preventing and treating functional disorders of central nervous system, particularly, Alzheimer's dementia, cerebral ischemia and spinal trauma, as well as for functional disorders of Peripheral nervous system, particularly, peripheral nervous system trauma and diabetic neurosis. As the pyrroquinolineguinones and their esters exhibit strong nerve growth factor production accelerating activity, they are suitably utilized for preventing and treating functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma, diabetic neuropathy, etc.
摘要翻译：提供含有恶唑吡咯并喹啉，吡咯醌啉醌和/或其酯作为活性成分的神经生长因子生产促进剂。由于恶唑吡咯并喹啉及其酯表现出这种生产促进活性，因此适用于预防和治疗中枢神经系统功能障碍，特别是阿尔茨海默氏痴呆，脑缺血和脊髓创伤，以及外周神经系统的功能障碍，外周神经系统创伤和糖尿病性神经症。由于吡咯喹啉酮及其酯表现出强烈的神经生长因子生产促进活性，因此适用于预防和治疗周围神经系统功能紊乱，特别是周围神经系统创伤，糖尿病性神经病变等。

7. 发明授权

US5344768A Process for the preparation of pyrrolo-quinoline quinone 失效
标题翻译：制备吡咯并喹啉醌的方法
公开(公告)号：US5344768A
公开(公告)日：1994-09-06
申请号：US91884
申请日：1993-07-14
申请人： Teizi Urakami
发明人： Teizi Urakami
IPC分类号： C12P17/18 , C12N1/20 , C12P17/16
CPC分类号： C12P17/182 , Y10S435/822 , Y10S435/824 , Y10S435/874
摘要： Pyrrolo-quinoline quinone (PQQ) is microbiologically produced by culturing a bacterium in a medium containing methanol, methylamine or a mixture thereof as a carbon source and recovering PQQ from the culture medium. The bacteria are strains of Methylobacterium, Ancylobacter, Hyphomicrobium, Xanthobacter, Thiobacillus, Microcyclus and Achromobacter.
摘要翻译：通过在含有甲醇，甲胺或其混合物作为碳源的培养基中培养细菌并从培养基中回收PQQ来微生物制备吡咯并喹啉醌（PQQ）。细菌是Methylobacterium，Ancyobacter，Hyphomicrobium，Xanthobacter，Thiobacillus，Microcyclus和Achromobacter的菌株。

8. 发明授权

US5760144A Aliphatic polyester polymer blends, methods for manufacturing the same, and methods for milding aliphatic polyester polymer blends 失效
标题翻译：脂肪族聚酯聚合物共混物，其制造方法和温和的脂族聚酯聚合物共混物的方法
公开(公告)号：US5760144A
公开(公告)日：1998-06-02
申请号：US678661
申请日：1996-07-11
申请人： Eiichi Ozeki , Jun Nagata , Teizi Urakami
发明人： Eiichi Ozeki , Jun Nagata , Teizi Urakami
IPC分类号： C08L67/04 , C08F20/00
CPC分类号： C08L67/04
摘要： Biodegradable polymer blends comprising of a polylactic acid or a copolymer containing lactic acid as the main constituent, and a polyhydroxyalkanoate or a copolymer containing two or more hydroxyalkanoic acids as the constituents; methods for controlling the rate of biodegradation of a polylactic acid or a copolymer containing lactic acid as the main constituent, by blending as above; methods for manufacturing such aliphatic polyester polymer blends; and methods for molding such polymer blends; are provided. The aliphatic polyester polymer blends obtained in the invention are colorless and clear, and have excellent biodegradabilities, as well as excellent mechanical strengths. The blends can be molded similarly as in conventional thermoplastic resins, so that they can be utilized in many industries, without problems in the waste product treatment after the use. Furthermore, molded products with excellent qualities are obtained from the blends, because of their improved moldabilities.
摘要翻译：包含聚乳酸或含有乳酸为主要成分的共聚物的生物可降解聚合物共混物和含有两种或多种羟基链烷酸作为组分的聚羟基链烷酸酯或共聚物; 通过上述混合来控制聚乳酸或含有乳酸的共聚物作为主要成分的生物降解速率的方法; 制造这种脂族聚酯聚合物共混物的方法; 以及用于模塑这种聚合物共混物的方法; 被提供。本发明中得到的脂族聚酯聚合物共混物是无色透明的，具有优异的生物降解能力以及优异的机械强度。共混物可以类似于常规热塑性树脂来模塑，使得它们可以在许多工业中使用，在使用后的废物处理中没有问题。此外，由于其改进的成型性，从共混物获得具有优良品质的成型产品。

9. 发明授权

US5236930A Oxazopyrroloquinolines and use of oxazopyrroloquinolines 失效
标题翻译：恶唑吡咯并喹啉和恶唑并吡咯啉喹啉的使用
公开(公告)号：US5236930A
公开(公告)日：1993-08-17
申请号：US826220
申请日：1992-01-23
申请人： Teizi Urakami , Mitsunori Oda , Chieko Itoh , Hisao Kobayashi , Toshio Nagai , Kazuhiro Sugamura
发明人： Teizi Urakami , Mitsunori Oda , Chieko Itoh , Hisao Kobayashi , Toshio Nagai , Kazuhiro Sugamura
IPC分类号： C07D498/14 , C12P17/18
CPC分类号： C07D498/14 , C12P17/188 , Y10S435/822 , Y10S435/863
摘要： The present invention provides a process for producing oxazopyrroloquinolines which comprises culturing microorganisms to produce pyrroloquinolinequinone and adding .alpha.-amino acids or monomethylamine to the resulting culture broth which contains the pyrroloquinolinequinone and from which cells of microorganisms are not separated, thereby to convert the pyrroloquinolinequinone to the corresponding oxazopyrroloquinolines.The thus obtained oxazopyrroloquinolines include novel compounds.The present invention further provides aldose reductase inhibitors, diabetic combined disease curing agents, immunopotentiating agents and liver disease inhibiting agents which contain as active ingredient these oxazopyrroloquinolines having excellent physiological activity.
摘要翻译：本发明提供一种生产恶唑并吡咯并喹啉的方法，其包括培养微生物以产生吡咯并喹啉醌，并向所得的含有吡咯并喹啉醌的培养液中加入α-氨基酸或一甲基胺，并且微生物细胞未分离，从而将吡咯并喹啉醌转化为对应的恶唑并吡咯啉喹啉。由此获得的恶唑并吡咯啉喹啉包括新化合物。本发明还提供了具有优异生理活性的醛糖还原酶抑制剂，糖尿病合并疾病固化剂，免疫增强剂和肝病抑制剂，其含有作为活性成分的恶唑吡咯并喹啉。

10. 发明授权

US5061711A Method of curing liver diseases by using pyrrolo quinoline quinone triesters and novel pyrrolo quinoline quinone triesters 失效
标题翻译：通过使用吡咯喹啉喹诺酮和新型吡咯喹啉喹诺酮治疗肝脏疾病的方法
公开(公告)号：US5061711A
公开(公告)日：1991-10-29
申请号：US592266
申请日：1990-10-03
申请人： Teizi Urakami , Mitsunori Oda , Chieko Itoh
发明人： Teizi Urakami , Mitsunori Oda , Chieko Itoh
IPC分类号： A61K31/47
CPC分类号： A61K31/47
摘要： Disclosed is a method of curing liver diseases by administration of pyrrolo quinoline quinon triesters (PQQ triesters). The PQQ triesters include PQQ triallyl ester and PQQ tribenzyl ester which are novel. The PQQ triesters being ester form, they have no toxicity and can be orally adminstered.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式